For example, the targeted drugs Pemigatinib and Ivosidenib for FGFR2 and IDH1, which have relatively high mutation rates, have become second-line treatment drugs for advanced ICC. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.